NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Wolfgang Miesbach on New Real-World Data for Haemophilia B Prophylaxis
Wolfgang Miesbach /LinkedIn
Oct 21, 2025, 11:08

Wolfgang Miesbach on New Real-World Data for Haemophilia B Prophylaxis

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”Thrilled to share new real-world data from Germany comparing three extended half-life Factor IX products for Haemophilia B prophylaxis: rIX-FP, rFIXFc, and N9-GP!

Multicenter chart review of 138 patients (mean age ~33 years) with moderate or severe haemophilia B from 31 centers and analysis of FIX consumption, dosing intervals, and bleeding rates over ~2 years:

Results
– Over 1/3 of rIX-FP and rFIXFc users achieved zero bleeds in the observation period, highlighting effective bleed prevention
– rIX-FP showed significantly lower FIX consumption (46.9 IU/kg/week) than rFIXFc (70.1 IU/kg/week) and similar to N9-GP (47.2 IU/kg/week)
– Extension of dosing intervals: Mean interval with rIX-FP reached 9.4 days, allowing less frequent infusions compared to 7.5 (rFIXFc) and 7.9 days (N9-GP)

Bleed rates: rIX-FP patients had lower annualised bleeding rates (ABR 0.8) vs. N9-GP (ABR 1.5, p=0.047) and comparable to rFIXFc (ABR 1.4)

Clinical Impact:

  • EHL FIX products offer flexible prophylaxis tailored to patient needs—key for supporting active lifestyles and improving adherence!
  • Real-world evidence builds confidence for clinicians considering switching or individualizing FIX therapy

Congratulations to the authors, PD Dr. Martin Olivieri and co-authors and thank you to CSL for supporting this study and generating robust evidence that advances patient-centered care in haemophilia B.”

Read the full article here.

Article: Comparing Real‑World Outcomes of Prophylaxis with Extended Half‑life Factor IX (rIX‑FP vs. rFIXFc and N9‑GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany

Authors: Martin Olivieri, Songkai Yan, Ying Yang , Radovan Tomic, Thomas Linhoff, Xiang Zhang, Douglass Drelich,Natalie Jakobs, Wolfgang Miesbach

Wolfgang Miesbach on New Real-World Data for Haemophilia B Prophylaxis

Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.

bleeding disorders Douglass Drelich Factor IX Frankfurt University Hospital Headlines Health Hematology Hemophilia B Hemostasis Hemostasis Today Martin Olivieri Medicine Natalie Jakobs Radovan Tomic Songkai Yan Thomas Linhoff Wolfgang Miesbach Xiang Zhang Ying Yang
NewsFeed